The Very Low Density Lipoprotein Receptor Regulates Urokinase Receptor Catabolism and Breast Cancer Cell Motility in Vitro*

Donna J. WebbDagger §, Diem H. D. Nguyen, Mauricio SankovicDagger , and Steven L. GoniasDagger parallel

From the Departments of Dagger  Pathology and  Biochemistry and Molecular Genetics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908

    ABSTRACT
Top
Abstract
Introduction
References

The very low density lipoprotein receptor (VLDLr) binds diverse ligands, including urokinase-type plasminogen activator (uPA) and uPA-plasminogen activator inhibitor-1 (PAI-1) complex. In this study, we characterized the effects of the VLDLr on the internalization, catabolism, and function of the uPA receptor (uPAR) in MCF-7 and MDA-MB-435 breast cancer cells. When challenged with uPA·PAI-1 complex, MDA-MB-435 cells internalized uPAR; this process was inhibited by 80% when the activity of the VLDLr was neutralized with receptor-associated protein (RAP). To determine whether internalized uPAR is degraded, we studied the catabolism of [35S]methionine-labeled uPAR. In the absence of exogenous agents, the uPAR catabolism t1/2 was 8.2 h. uPA·PAI-1 complex accelerated uPAR catabolism (t1/2 to 1.8 h), while RAP inhibited uPAR catabolism in the presence (t1/2 of 7.8 h) and absence (t1/2 of 16.9 h) of uPA·PAI-1 complex, demonstrating a critical role for the VLDLr. When MCF-7 cells were cultured in RAP, cell surface uPAR levels increased gradually, reaching a new steady-state in 3 days. The amount of uPA which accumulated in the medium also increased. Culturing in RAP for 3 days increased MCF-7 cell motility by 2.2 ± 0.1-fold and by 4.4 ± 0.3-fold when 1.0 nM uPA was added. The effects of RAP on MCF-7 cell motility were entirely abrogated by an antibody which binds uPA and prevents uPA binding to uPAR. MCF-7 cells that were cultured in RAP demonstrated increased levels of activated mitogen-activated protein kinases. Furthermore, the MEK inhibitor, PD098059, decreased the motility of RAP-treated cells without affecting control cultures. These studies suggest a model in which the VLDLr regulates autocrine uPAR-initiated signaling and thereby regulates cellular motility.

    INTRODUCTION
Top
Abstract
Introduction
References

The very low density lipoprotein receptor (VLDLr)1 is a member of the LDL receptor family, which includes the LDL receptor-related protein (LRP) and gp330/megalin (1, 2). These receptors have equivalent structural motifs and bind many of the same ligands, including apolipoprotein E-enriched chylomicron remnants, lipoprotein lipase, thrombospondin I, urokinase-type plasminogen activator (uPA), uPA-plasminogen activator inhibitor-1 (PAI-1) complex, and receptor-associated protein (RAP) (3-10). RAP is a 39-kDa protein chaperone which normally remains entirely intracellular (11, 12); however, when incubated with cells in culture, RAP blocks the binding of all known ligands to the VLDLr, LRP, and gp330/megalin (1, 13-15). Some ligands do not bind interchangeably to different members of the LDL receptor family. For example, activated alpha 2-macroglobulin and Pseudomonas exotoxin A bind only to LRP (16, 17).

In normal mouse development, LDL receptor homologues play distinct roles. Homozygous LRP deficiency is embryonic lethal (18). gp330/megalin-deficient mice survive gestation but die shortly thereafter due to abnormal lung development (19), whereas VLDLr-deficient mice survive but demonstrate decreased body weight, body mass index, and adipose tissue mass (20). These diverse phenotypes may reflect differences in the cells or tissues that express the various LDL receptor homologues. Alternatively, uncharacterized differences in receptor function may be involved.

Our laboratory recently identified a possible role for LRP as a regulator of cellular motility (21). We studied murine embryonic fibroblasts (MEFs) that are LRP-deficient and wild-type MEFs from the same mouse strain. These cells do not express the VLDLr or gp330/megalin (22). When allowed to migrate into denuded areas of vitronectin-coated cell culture wells, the LRP-deficient MEFs migrated almost twice as rapidly as wild-type cells (21). The increased motility of the LRP-deficient MEFs was at least partially explained by an increase in the level of cell surface uPAR and by an increase in the amount of uPA which accumulated in the conditioned medium of these cells (21). In diverse systems, uPA binding to uPAR promotes cellular migration by localizing cell surface proteinase activity, initiating signal transduction, and/or by regulating cellular adhesion (reviewed in Refs. 23 and 24).

Unlike LRP-deficient MEFs, vascular smooth muscle cells (VSMCs), which are treated with RAP to deactivate LDL receptor homologues, demonstrate decreased motility (25, 26). Interestingly, when MEFs are treated with RAP, while the migration assay is underway, no change in motility is observed (21). Although it was suggested that the uPA/uPAR system may be responsible for the changes in VSMC motility which accompany RAP treatment (25, 26), experiments were not performed to address this possibility. Other LRP ligands also may be involved. For example, thrombospondin 1 has been shown to inhibit the motility of VSMCs but not fibroblasts (27). It is also possible that RAP affects VSMCs differently than MEFs since VSMCs express VLDLr in addition to LRP (25, 28).

The hypothesis that LRP regulates cellular motility by altering the activity of the uPA/uPAR system is supported by recent studies demonstrating a role for LRP in uPAR endocytosis. uPA·PAI-1 complex, which is bound to uPAR, still binds to LRP (29). This interaction not only results in the internalization of uPA·PAI-1 complex, but promotes uPAR internalization as well (30). Thus, it has been proposed that uPA·PAI-1 complex bridges uPAR to LRP by forming a tetramolecular complex that undergoes endocytosis as an intact unit (18, 31). Internalized uPAR recycles back to the cell surface (31); however, the efficiency of recycling remains unclear. If the efficiency is less than 100%, then LRP may promote uPAR degradation in lysosomes, explaining why LRP-deficient MEFs have increased levels of cell surface uPAR (21).

The goal of the present investigation was to characterize the role of the VLDLr in the regulation of cell surface uPAR expression and cellular motility. Our studies were performed using breast cancer cell lines which express VLDLr but do not express LRP or gp330/megalin. When the VLDLr was neutralized, by culturing these cells in the presence of RAP, the level of cell surface uPAR increased gradually, reaching a new steady-state. The increase in cell surface uPAR was explained by a decrease in the rate of uPAR catabolism. Neutralizing the VLDLr also increased cellular motility. The increase in motility was entirely counteracted by an antibody which binds endogenously produced uPA and prevents uPAR ligation. We have previously shown that uPA promotes MCF-7 cell motility by activating the MAP kinases, extracellular signal-regulated kinase (ERK) 1 and ERK2 (32). In RAP-treated breast cancer cells, the levels of activated ERK1 and ERK2 were increased. Furthermore, the motility of RAP-treated cells was selectively inhibited by an antagonist of ERK-dependent signaling. These newly identified activities of the VLDLr indicate a potentially important role for this receptor as a regulator of cancer cell physiology.

    MATERIALS AND METHODS

Proteins and Reagents-- Single-chain uPA (scuPA), two-chain uPA (tcuPA), and a polyclonal antibody which specifically recognizes human uPAR were provided by Drs. Jack Henkin and Andrew Mazar (Abbott Laboratories). tcuPA was inactivated with diisopropyl fluorophosphate to form DIP-uPA, as described previously (32). A monoclonal antibody specific for the amino-terminal fragment of human uPA was from American Diagnostica. This antibody prevents the binding of uPA to cell surface uPAR (33). Polyclonal antibody 399R, which recognizes human uPAR, was also from American Diagnostica. PAI-1 was provided by Dr. Duane Day (Molecular Innovations). An expression construct encoding RAP as a glutathione S-transferase (GST) fusion protein was provided by Dr. Joachim Herz (University of Texas Southwestern Medical Center, Dallas, TX). GST-RAP was expressed and purified as described previously (34), and used without further modification. GST does not interfere with the function of RAP and does not independently affect any of the activities of LDL receptor homologues (34-36). The GST-RAP preparations used in this study contained less than 5 ng/ml endotoxin in a 0.2 µM solution, as determined by Pyrotell Limulus amebocyte clotting times. In control experiments, purified endotoxin, at 10 ng/ml, did not affect MCF-7 cell motility or uPAR expression. Na125I and [35S]methionine were from Amersham. The specific MAP kinase kinase (MEK) inhibitor, PD098059, was from Calbiochem. A polyclonal antibody which recognizes only active, phosphorylated ERK1 and ERK2 (p44/42) was provided by Dr. Michael Weber (University of Virginia). The polyclonal antibody which recognizes total ERK1 and ERK2 was from Zymed Laboratories Inc. (San Francisco, CA).

Cell Culture-- MDA-MB-435, which were from the ATCC, were cultured in L-15 medium (Life Technologies, Inc.) supplemented with 10% FBS, 10 µg/ml insulin, and penicillin/streptomycin. Low-passage (25-35) MCF-7 cells were kindly provided by Dr. Richard Santen (University of Virginia). These cells were cultured in RPMI (Life Technologies, Inc.) supplemented with 10% fetal bovine serum (FBS) (Hyclone Laboratories, Logan, UT), 100 units/ml penicillin, and 100 µg/ml streptomycin. MDA-MB-435 and MCF-7 cells were passaged at subconfluence with Cell Dissociation Buffer (Enzyme Free, Hank's based, Life Technologies, Inc.).

Ligand Blot and Immunoblot Analysis-- MDA-MB-435 and MCF-7 cells were solubilized in 50 mM HEPES, 0.5 M NaCl, 0.05% Tween 20, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml E-64, 10 µg/ml aprotinin, and 10 µg/ml leupeptin. Equal amounts of cellular protein (50 µg) were subjected to SDS-PAGE on 5% slabs and electrotransferred to nitrocellulose membranes (Millipore). The membranes were blocked with 50 mM Tris, 150 mM NaCl, pH 7.4 (TBS), containing 5% milk for 12 h at 4 °C. Ligand blot analysis was performed to detect membrane-associated RAP-binding proteins. The membranes were incubated with 200 nM GST-RAP in TBS with 5 mM CaCl2, 0.02% Tween 20, and 5% milk for 1 h at 25 °C. The membranes were then probed with GST-specific monoclonal antibody (Sigma) for 1 h at 25 °C, followed by goat anti-mouse IgG-peroxidase conjugate (Sigma). Secondary antibody was detected by enhanced chemiluminescence. VLDLr was detected by immunoblot analysis using similarly prepared nitrocellulose membranes and polyclonal anti-human VLDLr antibody (kindly provided by Drs. Keith McCrae and Mats Gåfvels). LRP heavy chain was detected with monoclonal antibody 8G1, provided by Dr. Dudley Strickland (American Red Cross, Rockville, MD).

Cellular Degradation of 125I-GST-RAP-- GST-RAP was radioiodinated, using Iodo-Beads (Pierce), to a specific activity of 1-2 µCi/µg. MCF-7 cells were washed with EBSS, 25 mM HEPES, pH 7.4, and 5 mg/ml bovine serum albumin (EHB medium). 125I-GST-RAP (10 nM) was then added to the cultures. A 100-fold molar excess of nonradiolabeled GST-RAP was added to some cultures so that specific RAP degradation could be determined. The cells were allowed to incubate for various periods of time at 37 °C. Cellular degradation of 125I-GST-RAP was detected by measuring the increase in trichloroacetic acid soluble radioactivity in the medium.

Binding of DIP-uPA to MCF-7 Cells-- MCF-7 cells were cultured in the presence or absence of GST-RAP (200 nM) for up to 5 days. The medium and GST-RAP were replaced daily. Our analysis of RAP catabolism by MCF-7 cells demonstrated that the concentration of GST-RAP in the medium decreased by less than 1% in each 24-h culturing period. Specific binding of DIP-uPA to RAP-treated and control MCF-7 cells was compared. DIP-uPA was radioiodinated with Iodo-Beads to a specific activity of 2-4 µCi/µg. The cultures were washed three times and then incubated with 125I-DIP-uPA (0.15-10 nM) in EHB for 4 h at 4 °C. In this uPA concentration range, high affinity binding to uPAR is selectively detected and low affinity interactions, such as those that might occur with the VLDLr, do not contribute significantly (3, 32, 37, 38). To quantitate specific binding, a 50-fold molar excess of nonradiolabeled DIP-uPA was added to some cultures. At the end of each binding experiment, the cultures were washed four times at 4 °C; cell associated radioactivity was recovered in M NaOH and quantitated in a gamma -counter. Cellular protein was determined by the bicinchoninic acid assay (Sigma). To calculate the number of specific uPA-binding sites per cell, the average mass of the MCF-7 cell was determined. Suspended cells were counted using a hemocytometer or a Coulter counter (yielding equivalent results) and then extracted for protein determination. The mass was 0.94 ± 0.07 ng/cell (n = 5).

uPA Accumulation in Conditioned Medium-- MCF-7 cells were incubated for 24 h in RPMI, without serum, in the presence or absence of 0.1 µM GST-RAP. Conditioned medium (CM) was recovered and concentrated 30-fold using Centricon concentrators with 10-kDa exclusion filters (Amicon). To detect plasminogen activator, concentrated CM was diluted 1:10 into solutions that contained 1.0 µM [Glu1]plasminogen and 0.5 mM Val-Leu-Lys-7-amido-4-methylcoumarin (VLK-AMC). Fluorescence emission at 460 nm (excitation at 380 nm) was monitored for 1 h at 25 °C. These tracings were converted using a first derivative function so that the resulting plots showed relative plasmin concentration against time. The absolute concentration of uPA in MCF-7 cell CM was determined by comparing the maximum velocity of plasminogen activation to a standard curve generated with different concentrations of purified tcuPA (0.1-10 nM). In control experiments, we determined that GST-RAP does not affect the kinetics of plasminogen activation or VLK-AMC hydrolysis. In additional control experiments, the selective uPA inhibitor, amiloride (1.0 mM) was used to demonstrate that uPA is the primary plasminogen activator in MCF-7 cell CM (39). Due to amiloride fluorescence, these experiments were performed using the plasmin-specific chromogenic substrate, VLK-p-nitroanilide.

VLDLr in uPAR Endocytosis-- MDA-MB-435 cells were chosen for these experiments since these cells have high levels of cell surface uPAR, compared with MCF-7 cells (Ref. 40 and our results). The MDA-MB-435 cells were treated with GST-RAP (1 µM) or vehicle for 15 min at 37 °C. uPA·PAI-1 complex (10 nM), which was pre-formed by reacting tcuPA with PAI-1 at a 1:1 molar ratio, or DIP-uPA (10 nM) was added to the medium and incubation was allowed to proceed for 20 min at 37 °C. The cultures were then placed on ice and washed 3 times with ice-cold EBSS, 10 mM HEPES, pH 7.4. A mild acid wash was then performed to dissociate uPA·PAI-1 complex or DIP-uPA (21, 31). The acid wash sequence was: 50 mM glycine-HCl, 100 mM NaCl, pH 3.0, for 10 min; 0.5 M HEPES, 0.1 M NaCl, pH 7.5; and then three washes with ice-cold EBSS, 10 mM HEPES, pH 7.4. Cell surface uPAR was quantitated by measuring specific binding of 125I-DIP-uPA (10 nM).

Kinetics of uPAR Catabolism and the Role of the VLDLr-- MDA-MB-435 cells were cultured for 12 h in methionine-free Dulbecco's modified Eagle's medium and then for 24 h in methionine-free Dulbecco's modified Eagle's medium supplemented with [35S]methionine (10 µCi/ml). The cultures were chased for 1 h with methionine-containing complete medium, washed, and incubated in fresh medium, in the presence or absence of uPA·PAI-1 complex (0.5 nM) and GST-RAP (200 nM). At various times, the cells were solubilized in 10 mM HEPES, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 100 mM N-octyl glucoside, 10 µg/ml E-64, 10 µg/ml aprotinin, and 10 µg/ml leupeptin, pH 7.4. [35S]Methionine-labeled uPAR was recovered from equal amounts of each cell extract by immunoprecipitation with uPAR-specific antibody (42 µg/ml), in the presence of 0.1% (w/v) ovalbumin and 10 mM EDTA. Antibody-antigen complexes were isolated with Protein A-agarose (Sigma). In control experiments, glycoprotein CD44 was recovered from the same cell extracts by immunoprecipitation using an antibody from Endogen (41) and rabbit anti-mouse IgG (Jackson Immunoresearch Laboratories). Immunoprecipitated proteins were subjected to SDS-PAGE and electrotransferred to nitrocellulose. [35S]Methionine-labeled uPAR or CD44 was quantitated by PhosphorImager analysis. Western blot analysis was performed to confirm the identity of the immunoprecipitated proteins.

Analysis of MAP Kinase Activation-- MCF-7 cells were cultured for 3 days in the presence of 200 nM GST-RAP or vehicle. Activation of ERK1 and ERK2 was then determined as described previously (32). Briefly, the medium was aspirated and replaced with ice-cold phosphate-buffered saline containing 1 mg/ml sodium orthovanadate. The cells were extracted at 4 °C with 1.0% Nonidet P-40, 50 mM HEPES, 100 mM NaCl, 2 mM EDTA, 1 µg/ml leupeptin, 2 µg/ml aprotinin, 0.4 mg/ml sodium orthovanadate, 0.4 mg/ml sodium fluoride, and 5 mg/ml dithiothreitol, pH 7.4. The extracts were subjected to SDS-PAGE on 12% slabs. Proteins were transferred to nitrocellulose membranes which were probed with antibodies that detect only phosphorylated (active) ERK1 and ERK2 or total ERK1 and ERK2.

Cellular Migration-- Cellular migration was studied using tissue culture-treated 6.5-mm Transwell chambers with 8.0 µm pore membranes (Costar). The underside surface of each membrane was coated with 20% FBS or with 5 µg/ml purified vitronectin for 2 h at 37 °C. The vitronectin was purified as described previously (42). When incubated with serum, the membranes become coated primarily with vitronectin, which serves as a major attachment and spreading factor (43). After coating, the membranes were blocked with 0.5% bovine serum albumin for 2 h at 37 °C and then washed with serum-free RPMI. MCF-7 cells, which had been treated with GST-RAP (200 nM) for 3 days and untreated cells were dissociated from monolayer cultures with Cell Dissociation Buffer (Life Technologies), washed with serum-free medium, and transferred to the top chamber of each Transwell at a density of 106 cells/ml (100 µl). The bottom chamber contained RPMI with 10% FBS. GST-RAP (200 nM) was added to both chambers of Transwells which contained cells that had been RAP treated. Cells were allowed to migrate for 6 h at 37 °C. The Transwell membranes were then recovered. Non-migrating cells were removed from the top surfaces with a cotton swab. The membranes were then fixed and stained with Diff-Quik (Dade Diagnostics). Cells that had migrated to the lower surfaces of the membranes were counted.

    RESULTS

VLDLr Expression in Breast Cancer Cell Lines-- Previous studies have demonstrated that MCF-7 cells express VLDLr, but not LRP or gp330/megalin (3, 44). Our ligand blot analyses confirmed this result (Fig. 1). When GST-RAP was incubated with proteins that were extracted from MCF-7 cells and immobilized on nitrocellulose, a single band with an apparent mass of 105 kDa was detected. The mobility of this band was identical to that of the VLDLr, as determined by immunoblot analysis. MDA-MB-435 cells, which express increased levels of uPAR compared with MCF-7 cells (40), also expressed VLDLr but no other members of the LDL receptor family, as determined by RAP ligand blotting. As a control, we prepared extracts of human embryonic fibroblasts. GST-RAP bound to a single high molecular mass band in the human embryonic fibroblast extracts. The mobility of this band was identical to that of the LRP heavy chain, as determined by immunoblot analysis. VLDLr was not detected in the human embryonic fibroblast extracts.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   VLDLr expression in breast cancer cell lines. Cell extracts prepared from MCF-7 and MDA-MB-435 human breast cancer cells and human embryonic fibroblasts were subjected to SDS-PAGE on 5% slabs and transferred to nitrocellulose. In RAP ligand blots, membranes were incubated with GST-RAP, followed by GST-specific monoclonal antibody and goat anti-mouse IgG-peroxidase conjugate. For immunoblots, the VLDLr was detected using polyclonal anti-human VLDLr antibody and LRP heavy chain was detected with monoclonal antibody 8G1.

Degradation of GST-RAP by MCF-7 Cells-- Studies analyzing the binding of 125I-GST-RAP to MCF-7 cells are shown in Fig. 2. Binding was specific and saturable; the Scatchard transformation (not shown) was linear (r2 = 0.94), suggesting that a single class of binding sites was detected. The KD was 6 nM and the Bmax was 110 fmol/mg of cell protein (n = 4). Assuming that RAP binds exclusively to the VLDLr, in MCF-7 cells, and that there is one RAP-binding site per VLDLr, then the Bmax corresponds to 60,000 copies of cell surface VLDLr/cell. RAP binding studies should be interpreted with caution since RAP has been reported to bind to cell surface sites that are independent of the LDL receptor family (45).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Binding and cellular degradation of GST-RAP by MCF-7 cells. In panel A, MCF-7 cells were incubated with increasing concentrations of 125I-GST-RAP for 4 h at 4 °C. The specific binding isotherm is shown. In panel B, degradation of GST-RAP by MCF-7 cells was determined by measuring trichloroacetic acid soluble radioactivity in the medium. Specific GST-RAP degradation is plotted as a function of time. Each point represents the mean of results from four separate experiments, each with duplicate determinations.

To study MCF-7 cell VLDLr function, we examined the kinetics of RAP degradation, using a nearly saturating concentration of 125I-GST-RAP (10 nM). RAP degradation is mediated only by receptors in the LDL receptor family (1, 13). Fig. 2, panel B, shows that after an anticipated lag phase, specific RAP degradation occurred at a nearly constant rate (1.4 ± 0.2 × 105 molecules/cell·h) for at least 6 h. Non-radiolabeled RAP (200 nM) inhibited 125I-GST-RAP degradation by 95 ± 3% (not shown). Based on this result, we chose to utilize 200 nM RAP to neutralize the VLDLr in the uPAR catabolism and cellular migration experiments (presented below). Assuming that all of the RAP-binding sites, detected in our equilibrium binding experiments, represent VLDLr, then approximately two molecules of RAP are internalized per copy of cell surface VLDLr per hour.

The linear RAP degradation curve shown in Fig. 2 indicates that cell surface VLDLr expression is not rapidly down-regulated by ligand. To determine whether prolonged culturing in RAP alters cell surface VLDLr expression, MCF-7 cells were cultured in the presence of 200 nM GST-RAP for 5 days. No change in the total level of VLDLr antigen was detected by immunoblot analysis (results not shown). Furthermore, the rate of GST-RAP degradation was unchanged; cells that were cultured in RAP degraded 549 ± 52 fmol of 125I-GST-RAP/mg of cell protein/h. Cells that were cultured for 5 days in vehicle degraded 532 ± 30 fmol of 125I-GST-RAP/mg of cell protein/h.

Regulation of Cell Surface uPAR Expression by the VLDLr-- LRP-deficient MEFs express 3-5-fold increased levels of cell surface uPAR compared with wild-type MEFs (21). To determine whether the VLDLr regulates cell surface uPAR expression, MCF-7 cells were cultured in the presence of 200 nM GST-RAP for up to 5 days. Cell surface uPAR was detected by measuring the binding of 10 nM 125I-DIP-uPA at 4 °C. As shown in Fig. 3, panel A, DIP-uPA binding increased progressively with time, reaching a maximum in 3 days. To confirm that the increase in uPA binding was due to uPAR, complete DIP-uPA-binding isotherms were generated using MCF-7 cells that had been treated with RAP for 3 days and control cells that were not RAP-treated (Fig. 3, panel B). For the control cells, the KD was 1.5 ± 0.3 nM and the Bmax was 5.9 ± 0.4 fmol/mg of cell protein (3,400 receptors/cell) (n = 4); these values are consistent with previously reported results (32). For RAP-treated cells, the KD was unchanged (1.4 ± 0.4 nM), as would be expected if the increase in uPA binding was due to an increase in cell surface uPAR. The Bmax was 19 ± 2 fmol/mg of cell protein (10,700 receptors/cell). Thus, prolonged culturing of MCF-7 cells in RAP increases the amount of available cell surface uPAR.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Binding of DIP-uPA to MCF-7 cells cultured in RAP. Panel A, MCF-7 cells were cultured in the presence or absence of GST-RAP for 1-5 days. Specific binding of 125I-DIP-uPA (10 nM) to RAP-treated MCF-7 cells (black-square) and vehicle-treated MCF-7 cells () was determined. Panel B, MCF-7 cells were cultured in GST-RAP or in vehicle for 3 days. Specific binding of 125I-DIP-uPA was then studied. Specific binding isotherms are shown for RAP-treated MCF-7 cells (black-square) and vehicle-treated MCF-7 cells (). Each point represents the mean of results from four separate experiments, each with duplicate determinations.

Evidence for VLDLr-mediated uPAR Endocytosis-- To determine whether the VLDLr mediates uPAR endocytosis, MDA-MB-435 cells were pretreated with RAP or vehicle for 15 min and then challenged with DIP-uPA or uPA·PAI-1 complex for 20 min at 37 °C. After acid washing the cells to remove uPAR-associated ligands, the level of cell surface uPAR was determined by measuring the binding of 125I-DIP-uPA (10 nM). Without prior ligand challenge, MDA-MB-435 cells bound 115 ± 5 fmol of DIP-uPA per mg of cell protein (Fig. 4). Cells that were treated with RAP for 20 min demonstrated unchanged specific 125I-DIP-uPA binding, as expected. 125I-DIP-uPA binding was also unchanged when cells were pretreated with nonradiolabeled DIP-uPA. This result confirms that DIP-uPA does not promote rapid uPAR internalization (30). By contrast, MDA-MB-435 cells, which were pretreated with uPA·PAI-1 complex, demonstrated a 90% decrease in 125I-DIP-uPA binding. Thus, uPA·PAI-1 complex promoted uPAR endocytosis in MDA-MB-435 cells. When the cells were pretreated with RAP and then exposed to uPA·PAI-1 complex, uPAR endocytosis was blocked by 80%. These results suggest that the VLDLr is required for uPA·PAI-1 complex-mediated uPAR endocytosis in MDA-MB-435 cells.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 4.   The effects of VLDLr on uPAR endocytosis. MDA-MB-435 cells were treated with RAP or vehicle for 15 min at 37 °C. Cultures were then pulse-exposed to DIP-uPA, uPA·PAI-1 complex or vehicle for 20 min and immediately chilled to 4 °C. After acid washing, specific binding of 125I-DIP-uPA (10 nM) was determined. Control represents cultures that were pretreated and pulse-exposed to vehicle. RAP represents cultures that were pretreated with RAP and then pulse-exposed to vehicle. DIP-uPA represents cultures that were pretreated with vehicle and pulse-exposed to DIP-uPA. uPA-PAI-1 represents cultures that were pretreated with vehicle and then pulse-exposed to uPA·PAI-1 complex. RAP + uPA-PAI-1 represents cultures that were pretreated with RAP and then pulse-exposed to uPA·PAI-1 complex.

The VLDLr Promotes uPAR Catabolism-- For VLDLr-mediated uPAR endocytosis to decrease the steady-state level of cell surface uPAR, either the distribution of uPAR between cell surface and intracellular pools must be shifted or a fraction of the internalized uPAR must be catabolized. To study uPAR catabolism, MDA-MB-435 cells were metabolically labeled with [35S]methionine. The cells were then cultured in the presence or absence of RAP. At various times, uPAR was recovered by immunoprecipitation. Representative immunoprecipitates are shown in Fig. 5, panel A. We confirmed that the major band was uPAR by immunoblot analysis (results not shown). The minor bands are probably proteins which co-immunoprecipitate with uPAR, as previously demonstrated by others (46-49).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 5.   Catabolism of uPAR in breast cancer cells. MDA-MB-435 cells were metabolically labeled with [35S]methionine and then incubated for various periods of time, in the presence or absence of RAP. Cells extracts were incubated with uPAR-specific antibody followed by Protein A-agarose. The immunoprecipitates were subjected to SDS-PAGE on 8% slabs and transferred to nitrocellulose. Radioactivity was quantitated by PhosphorImager analysis. Panel A shows immunoprecipitates of metabolically labeled cultures that were treated with RAP "+ RAP" or vehicle "- RAP" for the indicated times. In panel B, the amount of labeled uPAR recovered in immunoprecipitates from RAP-treated cells (black-square) and vehicle-treated cells (black-triangle) was plotted against time, as described in the text. Panel C shows equivalent graphs analyzing labeled uPAR recovery from cells treated with uPA·PAI-1 complex (black-triangle) or uPA·PAI-1 complex plus RAP (black-square).

The kinetics of uPAR catabolism are shown in Fig. 5, panel B. With both RAP-treated and control cells, linear graphs were obtained when the amount of labeled uPAR was plotted against time, according to the equation: log [at=0]/[at=x] kt/2.3 (Fig. 5, panel B). This result suggests that uPAR catabolism follows first-order kinetics. RAP significantly decreased the rate of uPAR catabolism. In the absence of RAP, the rate constant for uPAR catabolism was 8.5 × 10-2 h-1, corresponding to a uPAR survival t1/2 of 8.2 h. In the presence of RAP, the uPAR catabolism rate constant was 4.1 × 10-2 h-1, corresponding to a t1/2 of 16.9 h. Thus, RAP treatment caused an approximate doubling of the uPAR survival t1/2.

As a control, we studied the catabolism of [35S]methionine-labeled CD44. CD44 is a glycoprotein receptor which is expressed by MDA-MB-435 cells (50). When cells were cultured for 24 h in the absence of RAP, 70 ± 5% of the [35S]methionine-labeled CD44 remained (n = 4). In the presence of RAP, CD44 survival was unchanged; after 24 h, 68 ± 4% of the labeled CD44 remained. Thus, the effects of RAP on uPAR survival in MDA-MB-435 cells are specific.

Our results demonstrated that uPA·PAI-1 complex promotes uPAR internalization. To determine whether uPA·PAI-1 complex accelerates uPAR catabolism, we cultured metabolically labeled MDA-MB-435 cells in the presence of 0.5 nM uPA·PAI-1 complex. As shown in Fig. 5, panel C, the rate of uPAR catabolism was substantially increased; the first-order rate constant was 3.8 × 10-1 h-1, which corresponds to a t1/2 of 1.8 h. When RAP was added to the culture medium with uPA·PAI-1 complex, uPAR catabolism was inhibited; the rate constant was 8.9 × 10-2 h-1 and the t1/2 was 7.8 h. Thus, recycling of internalized uPAR is not 100% efficient. Instead, a significant fraction of the uPAR, which is internalized via a pathway that requires both uPA·PAI-1 complex and the VLDLr, is targeted for degradation.

Regulation of MCF-7 Cell Motility by the VLDLr and the Role of the uPA/uPAR System-- Cellular migration was studied using serum-coated Transwell membranes (Fig. 6, panel A). When MCF-7 cells were not pre-cultured in RAP or treated with uPA, 80 ± 18 cells penetrated the membranes within 6 h. ScuPA (1 nM) promoted MCF-7 cell migration, as previously reported (32). Pre-culturing in RAP for 3 days also increased MCF-7 cell motility (2.2 ± 0.1-fold, n = 8, p < 0.001); however, when RAP was incubated with the cells only while the migration assay was underway (no pre-culturing), cellular motility was unchanged (results not shown). ScuPA (1 nM) increased the motility of MCF-7 cells that had been pre-cultured in RAP still further (4.4 ± 0.3-fold, n = 8). When the Transwell membranes were coated with purified vitronectin instead of serum, identical results were obtained (results not shown). In control experiments, we demonstrated that GST-RAP does not affect MCF-7 cell proliferation.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 6.   Migration of RAP-treated MCF-7 cells and the role of the uPA/uPAR system. Panel A, MCF-7 cells that were precultured in RAP for 3 days and control cells that were cultured in vehicle (C) were allowed to migrate in serum-coated Transwell chambers in the presence or absence of scuPA, as shown. uPA-specific antibody (uPA-Ab) or non-immune IgG were also added as indicated. The number of cells migrating across the membrane is expressed as a percentage of that observed with control cells (no RAP pretreatment or scuPA exposure). Each bar represents the results of four separate experiments with triplicate determinations. Panel B, to study uPA secretion by MCF-7 cells, cultures were incubated in serum-free medium for 24 h, in the presence or absence of RAP. CM was collected and concentrated. The concentrated CM was incubated with plasminogen and VLK-AMC. Substrate hydrolysis is shown. "Background" shows the results obtained when plasminogen was activated using un-conditioned medium.

In our previous study (21), results were presented to suggest that autocrine activation of uPAR by endogenously produced uPA may be responsible for the increased motility of LRP-deficient MEFs. To determine whether the uPA/uPAR system is responsible for the increased motility of RAP-treated MCF-7 cells, we performed migration assays in the presence of a uPA-specific antibody that blocks uPA binding to uPAR (25 µg/ml). As shown in Fig. 6, the antibody had no effect on the motility of control cells, suggesting that autocrine activation of uPAR is not significant when the VLDLr is active. By contrast, the antibody completely neutralized the activity of exogenously added uPA, confirming the effectiveness of the antibody in this system. uPA-specific antibody also inhibited the motility of RAP-treated cells; these cells migrated comparably to cells that had not been precultured in RAP. In control experiments, non-immune mouse IgG (25 µg/ml) did not affect the migration of control MCF-7 cells or cells that had been cultured in RAP. Furthermore, non-immune IgG did not inhibit the response to exogenously added uPA. These results suggest that the increase in MCF-7 cell motility, which is induced by culturing in RAP, results from the activity of endogenously produced uPA.

Previous studies have either failed to detect uPA expression by MCF-7 cells or have detected very low levels (32, 40). Thus, we re-examined the question of uPA synthesis and secretion by MCF-7 cells using a highly sensitive assay in which plasminogen activator is detected in CM based on its ability to activate plasminogen. In three separate experiments, low levels of plasminogen activator were detected in CM isolated from control MCF-7 cells (Fig. 7, panel B). RAP significantly increased the recovery of plasminogen activator in the CM. The plasminogen activator was uPA since amiloride inhibited 96% of the activity (results not shown). The concentration of uPA in the CM recovered from RAP-treated cells (before concentrating) was 53 ± 8 pM (n = 4), as determined by comparison to a standard curve generated with purified tcuPA. Our activity assay detects scuPA and tcuPA; however, if PAI-1 was present in the CM, then the uPA concentration may have been underestimated (21).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 7.   MCF-7 cell migration in response to low concentrations of uPA. MCF-7 cells were allowed to migrate for 6 h in serum-coated Transwell membranes. The indicated concentrations of scuPA were added to both Transwell chambers. The response of MCF-7 cells to 50 pM uPA was studied in the presence of 25 µg/ml uPA-specific antibody (uPA-Ab) or 25 µg/ml uPAR-specific antibody (uPAR-Ab).

The concentration of uPA in MCF-7 cell CM was substantially lower than the KD for uPA binding to MCF-7 cell uPAR. Thus, new experiments were performed to determine whether exogenously added uPA, at very low concentrations, promotes MCF-7 cell motility. Fig. 7 shows that 50 pM uPA induced a statistically significant increase in MCF-7 cell motility (p < 0001). The activity of 50 pM scuPA was entirely neutralized by uPA-specific antibody and by uPAR-specific antibody 399R. In separate control experiments, we confirmed that antibody 399R completely inhibits the specific binding of 125I-DIP-uPA to MCF-7 cells. We have also shown that antibody 399R inhibits MAP kinase activation in response to uPA.2 Thus, these experiments demonstrate that uPA, at low concentrations, increases MCF-7 cell motility by a mechanism that requires binding to uPAR.

MAP Kinase Is Activated in RAP-treated MCF-7 Cells-- uPA activates ERK1 and ERK2 in MCF-7 cells and this response is necessary for uPA-promoted migration (32). Since RAP-treated MCF-7 cells have increased levels of cell surface uPAR and accumulate increased amounts of uPA, we undertook experiments to determine whether the extent of activation of ERK1 and/or ERK2 is increased in these cells as well. MCF-7 cells were cultured in standard FBS-supplemented medium, in the presence or absence of 200 nM GST-RAP for 3 days, and isolated without adding exogenous stimulants 12 h after the last change in medium. Activated ERK1 and ERK2 were detected by immunoblot analysis. A single experiment, in which six separate cultures were analyzed, is shown in Fig. 8, panel A. Culturing in RAP increased the levels of activated ERK1 and ERK2 by 2.8 ± 0.5- and 2.6 ± 0.6-fold, respectively (n = 6). Furthermore, PD098059, a selective inhibitor of MAP kinase kinase (MEK), inhibited the migration of RAP-treated cells without affecting the migration of control cells (Fig. 8, panel B). These studies suggest that a MAP kinase-dependent signaling pathway may be selectively activated in RAP-treated MCF-7 cells and that this pathway is required for enhanced motility on serum-coated surfaces.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 8.   Activation of ERK1 and ERK2 in VLDLr-neutralized cells. Panel A, immunoblot analysis detecting phosphorylated ERK1 and ERK2 and total ERK1 and ERK2 in six separate MCF-7 cell cultures which were analyzed simultaneously. Three of the cultures, which were maintained in the presence of GST-RAP for 3 days are designated by +. Levels of phosphorylated ERK1 and ERK2 were standardized by comparison to total ERK levels. The levels of phosphorylated ERK1 and ERK2 in RAP-treated cells were then compared with the levels detected in matched controls. Panel B, MCF-7 cells were allowed to migrate for 6 h through Transwells membranes that were precoated, on the underside surfaces, with FBS. The MEK inhibitor, PD098059, was added to the top chamber as indicated by +. For bars labeled Control, the cells were precultured in vehicle for 3 days and then allowed to migrate. For bars labeled RAP treated, the cells were precultured in RAP for 3 days and then RAP was added to both Transwell chambers. Cellular migration was standardized to that observed in control cells which were not RAP pretreated or treated with drug. Each bar represents the results of three separate experiments with triplicate determinations.


    DISCUSSION

Previous studies have shown that LRP and the VLDLr express similar activities as receptors for free uPA and uPAR-associated uPA·PAI-1 complex (3, 7, 18, 29). In this study, we demonstrated that the VLDLr, like LRP (30), mediates the endocytosis of uPAR through an indirect mechanism that depends on uPA·PAI-1 complex. When MDA-MB-435 cells were treated with uPA·PAI-1 complex at 37 °C, uPAR was rapidly internalized by a RAP-inhibited pathway. The most likely explanation for this result is that uPA·PAI-1 complex bridges the VLDLr and uPAR, on the cell surface, so that uPAR is internalized in clathrin-coated pits with the VLDLr. uPA binding to uPAR causes conformational changes in the receptor which could also be involved in the VLDLr interaction (51). In our 20-min endocytosis assays, DIP-uPA did not promote uPAR internalization, consistent with previous studies demonstrating that uPA·uPAR complex is stable on the cell surface (52, 53). However, we cannot rule out the possibility that uPA affects the rate of internalization of uPAR over a period of days.

In cells that express LRP, internalized uPAR is transferred to acidified endosomes where uPA·PAI complex is dissociated before the uPAR recycles back to the cell surface (18, 31, 54). If recycling is 100% efficient, the expected outcome of this pathway is to re-generate un-liganded uPAR on the cell surface, which is available to bind free uPA (1, 18, 31). In MCF-7 cells that were cultured for at least 3 days in RAP, the level of cell surface uPAR was increased. To explain these results, we studied the catabolism of metabolically labeled uPAR. When cultured in the presence of uPA·PAI-1 complex, MDA-MB-435 cells rapidly digested uPAR (t1/2 of 1.8 h versus 8.2 h) and this process was inhibited by RAP, indicating that at least a fraction of the uPAR, which is internalized in association with the VLDLr, is degraded. RAP also prolonged the survival of uPAR under standard cell culturing conditions, in the absence of exogenously added uPA·PAI-1 complex. At this time, we do not know whether this process depended on the formation of uPA·PAI-1 complex from endogenously produced uPA and PAI-1.

uPAR was still catabolized, albeit at a slower rate, when MDA-MB-435 cells were cultured in the presence of RAP. The residual catabolism may reflect bulk plasma membrane turnover, enzymatic release of uPAR from the cell surface, or the function of receptors outside the LDL receptor family. Nykjaer et al. (49) recently demonstrated that the mannose 6-phosphate/insulin-like growth factor-II receptor interacts with cell surface uPAR and targets uPAR for catabolism in lysosomes. Thus, cell surface uPAR levels may be controlled by diverse plasma-membrane interactions.

MCF-7 cells that were cultured in the presence of RAP for 3 days demonstrated increased motility on serum- or vitronectin-coated surfaces. When the cells were not precultured in RAP and allowed to migrate in Transwell chambers in the presence of RAP, motility was unchanged. Thus, the mechanism by which RAP promotes MCF-7 cell motility probably requires a change in the phenotype of the cell, which occurs slowly, as opposed to the more simple mechanism in which motility is influenced entirely by agents that accumulate at increased levels in solution when the VLDLr is blocked. Importantly, uPA-specific antibody inhibited the migration of MCF-7 cells that were exposed to exogenous uPA or precultured in RAP. The same antibody had no effect on the motility of control MCF-7 cells. These results provide evidence that autocrine activation of uPAR is responsible for the increase in the motility of RAP-treated cells. Apparently, in control cells, the level of cell surface uPAR and/or the amount of uPA which accumulates in the medium are too low to significantly affect motility.

Even though the level of cell surface uPAR in RAP-treated MCF-7 cells was increased to 104 sites per cell, the level of endogenously produced uPA was still low, compared with that observed in other cell lines, including LRP-deficient MEFs (21). Thus, we hypothesized that MCF-7 cells are highly sensitive to low concentrations of uPA and respond to low levels of uPAR ligation. When MCF-7 cells, which had not been precultured in RAP, were exposed to uPA, at concentrations from 50 pM to 1.0 nM, significant increases in motility were observed. Furthermore, an essential role for uPAR was demonstrated. Thus, MCF-7 cells are sensitive to concentrations of uPA that are substantially lower than the KD for uPAR binding. Although we did not measure the sensitivity to uPA of RAP pretreated MCF-7 cells, it is possible that these cells respond to even lower uPA concentrations, due to the increase in cell surface uPAR.

Further evidence that prolonged culturing in RAP affects the physiology of MCF-7 cells was obtained in studies of MAP kinase activation. Under standard cell-culturing conditions, the levels of activated ERK1 and ERK2 were significantly increased by RAP. While it is intriguing to speculate that the increase in activated ERK is caused by activation of the uPA/uPAR system, we have not yet conclusively linked these two processes. When treated with a high concentration of uPA, levels of activated ERK1 and ERK2 increase rapidly but transiently in MCF-7 cells (32). This response is substantially different than the low-level sustained activation of ERK1 and ERK2 demonstrated with RAP-treated MCF-7 cells. When cells are treated with epidermal growth factor, the kinetics of ERK activation depend on the epidermal growth factor concentration (55). High epidermal growth factor concentrations induce transient activation of ERK1 and ERK2 while lower epidermal growth factor concentrations induce sustained responses (55). Whether activation of ERK1 and ERK2, in response to uPA, is transient or sustained may depend on whether the cells are pulse-exposed to a high concentration of uPA, as in our previous study (32), or continuously exposed to a low level of uPA, as is hypothesized for RAP-treated cells.

The ability of the VLDLr to regulate the uPA/uPAR system may be considered in relation to multicellular tissues such as intact breast cancers. If the VLDLr is expressed by malignant epithelial cells, as previously demonstrated (3, 44), it should regulate pericellular uPA levels, irrespective of whether the uPA is synthesized by cancer cells or benign stromal cells. Alternatively, our results suggest that uPAR regulation depends on co-expression of uPAR and the VLDLr by the same cell type. LRP, which is expressed by macrophages and fibroblasts, may also regulate uPA levels in the microenvironment of the cancer but will not regulate cell surface uPAR levels in the malignant cells, if these cells are LRP negative. Thus, members of the LDL receptor family may regulate the activity of the uPA/uPAR system within cancers by both autocrine and paracrine mechanisms.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant CA-53462 and Department of the Army Breast Cancer Research Program Grant 94-J-4447.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Fellow of the American Heart Association, Virginia Affiliate.

parallel To whom correspondence should be addressed: University of Virginia Health Sciences Center, Depts. of Pathology and Biochemistry and Molecular Genetics, Box 214, Charlottesville, VA 22908. Tel.: 804-924-9192; Fax: 804-982-0283; E-mail: SLG2T{at}VIRGINIA.EDU.

2 D. H. D. Nguyen et al., unpublished results.

    ABBREVIATIONS

The abbreviations used are: VLDLr, very low density lipoprotein receptor; LDL, low density lipoprotein receptor; LRP, low-density lipoprotein receptor-related protein; RAP, receptor-associated protein; uPA, urokinase-type plasminogen activator; uPAR, urokinase receptor; MEF, murine embryonic fibroblasts; PAI-1, plasminogen activator inhibitor-1; ERK, extracellular signal-regulated kinase; GST, glutathione S-transferase; FBS, fetal bovine serum; CM, conditioned medium; VSMC, vascular smooth muscle cells; scuPA, single-chain uPA; tcuPA, two-chain uPA; DIP-µPA, diisopropylphospho-uPA; MAP, mitogen-activated protein kinase; PAGE, polyacrylamide gel electrophoresis; VLK-AMC, Val-Leu-Lys-7-amido-4-methylcoumarin.

    REFERENCES
Top
Abstract
Introduction
References
  1. Strickland, D. K., Kounnas, M. Z., and Argraves, W. S. (1995) FASEB J. 9, 890-898[Abstract/Free Full Text]
  2. Krieger, M., and Herz, J. (1994) Annu. Rev. Biochem. 63, 601-637[CrossRef][Medline] [Order article via Infotrieve]
  3. Heegaard, C. W., Simonsen, A. C. W., Oka, K., Kjøller, L., Christensen, A., Madsen, B., Ellgaard, L., Chan, L., and Andreasen, P. A. (1995) J. Biol. Chem. 270, 20855-20861[Abstract/Free Full Text]
  4. Martensen, P. M., Oka, K., Christensen, L., Rettenberger, P. M., Petersen, H. H., Christensen, A., Chan, L., Heegaard, C. W., and Andreasen, P. A. (1997) Eur. J. Biochem. 248, 583-591[Abstract]
  5. Willnow, T. E., Goldstein, J. L., Orth, K., Brown, M. S., and Herz, J. (1992) J. Biol. Chem. 267, 26172-26180[Abstract/Free Full Text]
  6. Moestrup, S. K., Nielsen, S., Andreasen, P., Jørgensen, K. E., Nykjær, A., Røigaard, H., Gliemann, J., and Christensen, E. I. (1993) J. Biol. Chem. 268, 16564-16570[Abstract/Free Full Text]
  7. Argraves, K. M., Battey, F. D., MacCalman, C. D., McCrae, K. R., Gåfvels, M., Kozarsky, K. F., Chappell, D. A., Strauss, J. F., III, and Strickland, D. K. (1995) J. Biol. Chem. 270, 26550-26557[Abstract/Free Full Text]
  8. Stefansson, S., Kounnas, M. Z., Henkin, J., Mallampalli, R. K., Chappell, D. A., Strickland, D. K., and Argraves, W. S. (1995) J. Cell Sci. 108, 2361-2368[Abstract/Free Full Text]
  9. Takahashi, S., Suzuki, J., Kohno, M., Oida, K., Tamai, T., Miyabo, S., Yamamoto, T., and Nakai, T. (1995) J. Biol. Chem. 270, 15747-15754[Abstract/Free Full Text]
  10. Mikhailenko, I., Krylov, D., Argraves, K. M., Roberts, D. D., Liau, G., and Strickland, D. K. (1997) J. Biol. Chem. 272, 6784-1691[Abstract/Free Full Text]
  11. Willnow, T. E., Rohlmann, A., Horton, J., Otani, H., Braun, J. R., Hammer, R. E., and Herz, J. (1996) EMBO J. 15, 2632-2639[Abstract]
  12. Bu, G., Geuze, H. J., Strous, G. J., and Schwartz, A. L. (1995) EMBO J. 14, 2269-2280[Abstract]
  13. Herz, J., Goldstein, J. L., Strickland, D. K., Ho, Y. K., and Brown, M. S. (1991) J. Biol. Chem. 266, 21232-21238[Abstract/Free Full Text]
  14. Battey, F. D., Gåfvels, M. E., FitzGerald, D. J., Argraves, W. S., Chappell, D. A., Strauss, J. F., III, and Strickland, D. K. (1994) J. Biol. Chem. 269, 23268-23273[Abstract/Free Full Text]
  15. Kounnas, M. Z., Argraves, W. S., and Strickland, D. K. (1992) J. Biol. Chem. 267, 21162-21166[Abstract/Free Full Text]
  16. Strickland, D. K., Ashcom, J. D., Williams, S., Burgess, W. H., Migliorini, M., and Argraves, W. S. (1990) J. Biol. Chem. 265, 17401-17404[Abstract/Free Full Text]
  17. Kounnas, M. Z., Morris, R. E., Thompson, M. R., FitzGerald, D. J., Strickland, D. K., and Saelinger, C. B. (1992) J. Biol. Chem. 267, 12420-12423[Abstract/Free Full Text]
  18. Herz, J., Clouthier, D. E., and Hammer, R. E. (1992) Cell. 71, 411-421[Medline] [Order article via Infotrieve]
  19. Willnow, T. E., Hilpert, J., Armstrong, S. A., Rohlmann, A., Hammer, R. E., Burns, D. K., and Herz, J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8460-8464[Abstract/Free Full Text]
  20. Frykman, P. K., Brown, M. S., Yamamoto, T., Goldstein, J. L., and Herz, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8453-8457[Abstract]
  21. Weaver, A. M., Hussaini, I. M., Mazar, A., Henkin, J., and Gonias, S. L. (1997) J. Biol. Chem. 272, 14372-14379[Abstract/Free Full Text]
  22. Willnow, T. E., and Herz, J. (1994) J. Cell Sci. 107, 719-726[Abstract/Free Full Text]
  23. Andreasen, P. A., Kjøller, L., Christensen, L., and Duffy, M. J. (1997) Int. J. Cancer. 72, 1-22[CrossRef][Medline] [Order article via Infotrieve]
  24. Conese, M., and Blasi, F. (1995) Bailliere's Clin. Heamatol. 8, 365-389[Medline] [Order article via Infotrieve]
  25. Wijnberg, M. J., Quax, P. H. A., Nieuwenbroek, N. M. E., and Verheijen, J. H. (1997) Thromb. Haemost. 78, 880-886[Medline] [Order article via Infotrieve]
  26. Okada, S. S., Grobmyer, S. R., and Barnathan, E. S. (1996) Arterioscler. Thromb. Vasc. Biol. 16, 1269-1276[Abstract/Free Full Text]
  27. Tolsma, S. S., Stack, M. S., and Bouck, N. (1997) Microvasc. Res. 54, 13-26[CrossRef][Medline] [Order article via Infotrieve]
  28. Weaver, A. M., Lysiak, J. J., and Gonias, S. L. (1997) J. Lipid Res. 38, 1841-1850[Abstract]
  29. Nykjaer, A., Kjøller, L., Cohen, R. L., Lawrence, D. A., Garni-Wagner, B. A., Todd, R. F., III, van Zonneveld, A.-J., Gliemann, J., and Andreasen, P. A. (1994) J. Biol. Chem. 269, 25668-25676[Abstract/Free Full Text]
  30. Conese, M., Nykjær, A., Petersen, C. M., Cremona, O., Pardi, R., Andreasen, P. A., Gliemann, J., Christensen, E. I., and Blasi, F. (1995) J. Cell Biol. 131, 1609-1622[Abstract]
  31. Nykjær, A., Conese, M., Christensen, E. I., Olson, D., Cremona, O., Gliemann, J., and Blasi, F. (1997) EMBO J. 16, 2610-2620[Abstract/Free Full Text]
  32. Nguyen, D. H. D., Hussaini, I. M., and Gonias, S. L. (1998) J. Biol. Chem. 273, 8502-8507[Abstract/Free Full Text]
  33. Chucholowski, N., Schmitt, M., Rettenberger, P., Schüren, E., Moniwa, N., Goretzki, L., Wilhelm, O., Weidle, U., Jänicke, F., and Graeff, H. (1992) Fibrinolysis 4, 95-102
  34. Webb, D. J., Hussaini, I. M., Weaver, A. M., Atkins, T. L., Chu, C. T., Pizzo, S. V., Owens, G. K., and Gonias, S. L. (1995) Eur. J. Biochem. 234, 714-722[Abstract]
  35. Williams, S. E., Ashcom, J. D., Argraves, W. S., and Strickland, D. K. (1992) J. Biol. Chem. 267, 9035-9040[Abstract/Free Full Text]
  36. Warshawsky, I., Bu, G., and Schwartz, A. L. (1993) J. Biol. Chem. 268, 22046-22054[Abstract/Free Full Text]
  37. Appella, E., Robinson, E. A., Ullrich, S. J., Stoppelli, M. P., Corti, A., Cassani, G., and Blasi, F. (1987) J. Biol. Chem. 262, 4437-4440[Abstract/Free Full Text]
  38. Estreicher, A., Wohlwend, A., Belin, D., Schleuning, W. D., and Vassalli, J.-D. (1989) J. Biol. Chem. 264, 1180-1189[Abstract/Free Full Text]
  39. Vassalli, J., and Belin, D. (1987) FEBS Lett. 214, 187-191[CrossRef][Medline] [Order article via Infotrieve]
  40. Holst-Hansen, C., Johannessen, B., Hoyer-Hansen, G., Romer, J., Ellis, V., and Brunner, N. (1996) Clin. & Exp. Metastasis 14, 297-307[Medline] [Order article via Infotrieve]
  41. Telen, M. J., Palker, T. J., and Haynes, B. F. (1984) Blood 64, 599-606[Abstract]
  42. Yatohgo, T., Izumi, M., Kashiwagi, H., and Hayashi, M. (1988) Cell Struct. Funct. 13, 281-292[Medline] [Order article via Infotrieve]
  43. Hayman, E. G., Pierschbacher, M. D., Ohgren, Y., and Ruoslahti, E. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 4003-4007[Abstract]
  44. Simonsen, A. C. W., Heegaard, C. W., Rasmussen, L. K., Ellgaard, L., Kjøller, L., Christensen, A., Etzerodt, M., and Andreasen, P. A. (1994) FEBS Lett. 354, 279-283[CrossRef][Medline] [Order article via Infotrieve]
  45. Vassiliou, G., and Stanley, K. K. (1994) J. Biol. Chem. 269, 15172-15178[Abstract/Free Full Text]
  46. Busso, N., Masur, S. K., Lazega, D., Waxman, S., and Ossowski, L. (1994) J. Cell Biol. 126, 259-270[Abstract]
  47. Resnati, M., Guttinger, M., Valcamonica, S., Sidenius, N., Blasi, F., and Fazioli, F. (1996) EMBO J. 15, 1572-1582[Abstract]
  48. Konakova, M., Ferdinand, H., and Schleuning, W.-D. (1998) Eur. J. Biochem. 253, 421-429[Abstract]
  49. Nykjaer, A., Christensen, E. I., Vorum, H., Hager, H., Petersen, C. M., Røigaard, H., Min, H. Y., Vilhardt, F., Møller, L. B., Kornfeld, S., and Gliemann, J. (1998) J. Cell Biol. 141, 815-828[Abstract/Free Full Text]
  50. Fichtner, I., Dehmel, A., Naundorf, H., and Finke, L. H. (1997) Anticancer Res. 17, 3633-3646[Medline] [Order article via Infotrieve]
  51. Higazi, A. A-R., Upson, R. H., Cohen, R. L., Manuppello, J., Bognacki, J., Henkin, J., McCrae, K. R., Kounnas, M. Z., Strickland, D. K., Preissner, K. T., Lawler, J., and Cines, D. B. (1996) Blood 88, 542-551[Abstract/Free Full Text]
  52. Cubellis, M. V., Wun, T.-C., and Blasi, F. (1990) EMBO J. 9, 1079-1085[Abstract]
  53. Jensen, P. H., Christensen, E. I., Ebbesen, P., Gliemann, J., and Andreasen, P. A. (1990) Cell Regul. 1, 1043-1056[Medline] [Order article via Infotrieve]
  54. Nykjaer, A., Petersen, C. M., Møller, B., Jensen, P. H., Moestrup, S. K., Holtet, T. L., Etzerodt, M., Thøgersen, H. C., Munch, M., Andreasen, P. A., and Gliemann, J. (1992) J. Biol. Chem. 267, 14543-14546[Abstract/Free Full Text]
  55. Silvy, M., Martin, P-M., Chajry, N., and Berthois, Y. (1998) Endocrinology 139, 2382-2391[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.